The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Skyrizi (risankizumab) is the first IL-23-selective ... integrin inhibitors – as well as older branded and biosimilar TNF inhibitors including AbbVie's own blockbuster Humira (adalimumab).

as well as AbbVie's TNF inhibitor Humira (adalimumab) and lower-cost biosimilars. Meanwhile, AbbVie has also filed for approval of its IL-23 inhibitor Skyrizi (risankizumab) in UC, and J&J is ...

risankizumab, sarilumab, secukinumab, tocilizumab, ustekinumab Increased risk of serious infections, increased risk of some cancers DMARD = disease-modifying antirheumatic drug; TNF = tumor necrosis ...

After hours: March 14 at 7:46:23 PM EDT Loading Chart for TNFA ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...

Department of Medicine 1, University of Erlangen-Nuremberg, Erlangen, Germany Correspondence to Dr Christoph Becker, 1. Department of Medicine, University of Erlangen-Nuremberg, Hartmannstrasse 14, 91 ...